Brief: Xbiotech Announces First Patient In Phase 2 Study Evaluating Subcutaneous MABP1 In Patients With Hidradenitis Suppurativa
10/07/2018 13:09
July 10 (Reuters) - XBiotech Inc XBIT.O :
* XBIOTECH ANNOUNCES FIRST PATIENT IN PHASE 2 STUDY
EVALUATING
SUBCUTANEOUS MABP1 IN PATIENTS WITH HIDRADENITIS SUPPURATIVA
Source text for Eikon: ID:nGNE2Nj1f
Further company coverage: XBIT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke